Infectious Diseases and Therapy

Scope & Guideline

Empowering discovery in infectious disease therapy.

Introduction

Welcome to the Infectious Diseases and Therapy information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Infectious Diseases and Therapy, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2193-8229
PublisherSPRINGER LONDON LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationINFECT DIS THER / Infect. Dis. Ther.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND

Aims and Scopes

Infectious Diseases and Therapy aims to address critical issues in the field of infectious diseases through rigorous research, clinical trials, and real-world evidence. The journal covers a broad scope of infectious diseases, emphasizing innovative therapeutic approaches, epidemiological trends, and health policy implications.
  1. Clinical Effectiveness and Safety of Antimicrobials:
    The journal focuses extensively on the effectiveness and safety profiles of various antimicrobial agents, including novel antibiotics and antiviral therapies, particularly in resistant infections.
  2. Epidemiological Studies and Disease Burden:
    A significant emphasis is placed on epidemiological research that assesses the burden of infectious diseases, hospitalizations, and mortality rates across different populations and regions.
  3. Vaccination Strategies and Public Health Impact:
    The journal explores vaccination strategies, their effectiveness, and the economic implications of vaccination programs in controlling infectious diseases.
  4. Emerging Infectious Diseases and Therapeutic Innovations:
    Research on emerging infectious diseases and innovative therapeutic approaches, including monoclonal antibodies and novel vaccine candidates, is a key area of focus.
  5. Antimicrobial Resistance:
    The journal addresses the growing concern of antimicrobial resistance, providing insights into resistance patterns, risk factors, and strategies for effective management.
The journal has seen a surge in certain themes that reflect current global health priorities, particularly in response to the COVID-19 pandemic and other emerging infectious diseases.
  1. COVID-19 Research and Long-Term Effects:
    A significant increase in studies related to COVID-19, including its long-term effects, treatment efficacy, and vaccination strategies, has been observed as the pandemic continues to evolve.
  2. Real-World Evidence and Effectiveness Studies:
    There is a growing trend towards publishing real-world evidence studies that assess the effectiveness of treatments and interventions in diverse patient populations.
  3. Economic Evaluations and Cost-Effectiveness Analyses:
    Research focusing on the economic impact of infectious diseases and the cost-effectiveness of interventions has gained traction, reflecting a need for sustainable healthcare solutions.
  4. Innovative Therapeutic Approaches:
    Emerging therapeutic strategies, including microbiome-based therapies and novel antiviral agents, are increasingly featured, highlighting the journal's commitment to advancing treatment options.
  5. Global Health Perspectives:
    An increasing number of publications focus on global health issues, emphasizing the need for collaborative approaches to tackle infectious diseases in low- and middle-income countries.

Declining or Waning

While the journal has a broad and evolving scope, some themes have seen a decline in focus over recent years. This may reflect shifts in research priorities or changes in the landscape of infectious diseases.
  1. Traditional Antibiotic Therapies:
    There has been a noticeable decrease in publications focused solely on traditional antibiotic therapies, as the field shifts towards exploring combination therapies and novel agents to combat resistant strains.
  2. Viral Infections Outside of COVID-19:
    Research on viral infections other than COVID-19 has waned, as the pandemic has dominated the discourse and research funding, leading to less attention on other viral pathogens.
  3. Non-communicable Disease Intersections:
    The intersection of infectious diseases with non-communicable diseases has received less emphasis, possibly overshadowed by the urgent need to address acute infectious threats.

Similar Journals

Emerging Microbes & Infections

Connecting researchers to combat emerging microbes.
Publisher: TAYLOR & FRANCIS LTDISSN: Frequency: 1 issue/year

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

ANTIVIRAL THERAPY

Exploring innovative therapies for viral infections.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi

Connecting researchers to combat emerging infection challenges.
Publisher: BILIMSEL TIP YAYINEVIISSN: 1300-932XFrequency: 4 issues/year

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi, published by BILIMSEL TIP YAYINEVI, is a leading journal dedicated to the field of infection diseases and clinical microbiology. With an ISSN of 1300-932X and an E-ISSN of 2602-2842, this journal has been an established Open Access platform since 1999, allowing researchers worldwide to access critical studies and advancements without barriers. The journal aims to disseminate high-quality research articles, reviews, and case studies that address emerging challenges in infection management and microbiological practices. By fostering a collaborative environment for professionals, researchers, and students alike, Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi plays a vital role in advancing knowledge and practices within the microbiological and clinical spheres. Its commitment to open access ensures that invaluable resources are widely available, supporting the growth and development of innovation in the medical field.

CLINICAL INFECTIOUS DISEASES

Pioneering research for a healthier tomorrow.
Publisher: OXFORD UNIV PRESS INCISSN: 1058-4838Frequency: 24 issues/year

Clinical Infectious Diseases, published by Oxford University Press Inc, is a premier journal in the fields of infectious diseases and microbiology, distinguished by its esteemed Q1 ranking in both categories as of 2023. Since its inception, the journal has served as a vital platform for disseminating cutting-edge research and significant advancements in the diagnosis, treatment, and prevention of infectious diseases. With a broad scope encompassing clinical trials, epidemiological studies, and public health research, it targets a diverse readership, including researchers, healthcare professionals, and students. The journal's robust reputation is underscored by its impactful contributions to scientific understanding, making it a critical resource for those striving to combat infectious diseases globally. Clinical Infectious Diseases is not open access but offers various subscription options, ensuring comprehensive access to its high-quality content. With a historical continuity from 1985 to present, the journal remains at the forefront of medical research, paving the way for future innovations in the field.

Infectious Diseases and Clinical Microbiology

Bridging research and clinical practice in infectious health.
Publisher: DOC DESIGN INFORMATICS CO LTDISSN: 2667-646XFrequency: 4 issues/year

Infectious Diseases and Clinical Microbiology is a pivotal journal dedicated to advancing our understanding of infectious diseases through rigorous scientific research and clinical practices. Published by DOC DESIGN INFORMATICS CO LTD, this journal serves as a vital platform for researchers, healthcare professionals, and students keen on enhancing their knowledge of microbiological sciences and the clinical implications of infectious agents. With an ISSN of 2667-646X, it aims to disseminate significant findings in the field, enriching the scholarly dialogue surrounding infectious diseases. While currently operating under a traditional access model, the journal encourages global collaboration and knowledge sharing, striving to make a meaningful impact in tackling the challenges posed by infectious diseases. Its content aims to bridge the gap between laboratory research and clinical application, making it an essential resource in the contemporary landscape of global health.

EMERGING INFECTIOUS DISEASES

Shaping the Future of Epidemiology and Public Health
Publisher: CENTERS DISEASE CONTROL & PREVENTIONISSN: 1080-6040Frequency: 12 issues/year

Emerging Infectious Diseases, published by the Centers for Disease Control and Prevention, is a leading open-access journal that has been dedicated to the field of epidemiology, infectious diseases, and medical microbiology since its inception in 1995. With an impressive impact factor placing it in the Q1 quartile rankings for multiple categories including Epidemiology, Infectious Diseases, and Medical Microbiology, this journal serves as a vital resource for researchers, practitioners, and students dedicated to combating the challenges posed by emerging infectious diseases. The journal's distinguished Scopus ranks further highlight its global influence, ranking #10 in Epidemiology, #26 in Infectious Diseases, and #13 in Medical Microbiology, all within the top percentiles. Accessible and targeted, Emerging Infectious Diseases publishes seminal research and reviews that contribute to the understanding and management of infectious diseases, ensuring that critical insights reach a broad audience. The journal encourages contributions that advance the scientific community’s knowledge and responses to public health challenges.

EPIDEMIOLOGY AND INFECTION

Connecting Research to Global Health Solutions
Publisher: CAMBRIDGE UNIV PRESSISSN: 0950-2688Frequency: 1 issue/year

EPIDEMIOLOGY AND INFECTION is a premier open-access journal published by Cambridge University Press, dedicated to advancing the field of epidemiology and infectious diseases. With an ISSN of 0950-2688 and E-ISSN of 1469-4409, this journal has been at the forefront of disseminating impactful research since its inception in 1970. As of 2023, it holds a prestigious Q2 ranking in both the fields of Epidemiology and Infectious Diseases, reflecting its significant contribution to these critical areas of study, with Scopus rankings placing it at #70 in Epidemiology and #163 in Infectious Diseases. The journal aims to publish high-quality, peer-reviewed studies that contribute to our understanding and management of infectious diseases globally. Operating under an open-access model since 2020, EPIDEMIOLOGY AND INFECTION ensures that research is accessible to a wide audience, fostering collaboration and innovation among researchers, professionals, and students alike. With a commitment to excellence, this journal is an essential resource for those looking to stay abreast of the latest developments in epidemiological research and infectious disease management.

International Journal of Antimicrobial Agents

Connecting Researchers and Clinicians in the Battle Against Infections
Publisher: ELSEVIERISSN: 0924-8579Frequency: 12 issues/year

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

IJID Regions

Advancing global health knowledge through open access research.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

IJID Regions is a pioneering open access journal published by Elsevier, focusing on the critical fields of epidemiology, infectious diseases, and public health. Established in 2021, the journal aims to provide a platform for disseminating high-quality, innovative research that addresses pressing health issues and informs evidence-based practices in communities around the globe. With its impact factors reflecting a Tier Q2 and Q3 ranking in various medical subcategories on the Scopus platform, IJID Regions is positioned as a valuable resource for researchers, health professionals, and policy-makers striving to enhance public health outcomes. This journal not only champions open access since its inception, promoting the free flow of information, but also welcomes contributions that shed light on contemporary challenges in environmental and occupational health. Its commitment to fostering dialogue and collaboration in the health sciences is paramount, making it an essential read for those engaged in advancing public health knowledge and initiatives.

New Microbes and New Infections

Bridging gaps in understanding novel infectious agents.
Publisher: ELSEVIER SCI LTDISSN: Frequency: 6 issues/year

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.